IGC Pharma (IGC) EBIT Margin (2010 - 2025)
IGC Pharma (IGC) posted quarterly EBIT Margin of 1517.8% for Q3 2025, down 109062.0% year-over-year from N/an in Q3 2024, and down 161.33% quarter-over-quarter from 580.79% in Q2 2025.
IGC Pharma (IGC) EBIT Margin (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported EBIT Margin for 16 consecutive years, with 1517.8% the latest figure, recorded in Q3 2025.
- In Q3 2025, EBIT Margin fell 109062.0% year-over-year to 1517.8%; the TTM figure through Sep 2025 stood at 731.92% (up 5625.0% YoY), while the FY2026 annual figure was 775.39%, down 18956.0% from the prior year.
- EBIT Margin fell to 1517.8% in Q3 2025 per IGC's latest filing, from 580.79% in the prior quarter.
- Across five years, EBIT Margin topped out at 385.41% in Q2 2023 and bottomed at 7764.29% in Q3 2021.
- Historically, EBIT Margin has averaged 1829.08% across 5 years, with a median of 1231.68% in 2022.
- Annual changes were most pronounced in 2021 — EBIT Margin tumbled 642349 bps — and 2022, when it jumped 653260 bps.
- IGC Pharma's EBIT Margin stood at 1679.58% in 2021, then soared by 59 bps to 686.14% in 2022, then tumbled by 114 bps to 1469.61% in 2023, then jumped by 50 bps to 730.74% in 2024, then sank by 108 bps to 1517.8% in 2025.
- Business Quant data shows IGC's EBIT Margin at 1517.8% in Q3 2025, 580.79% in Q2 2025, and 428.18% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,517.80% |
| Jun 30, 2025 | -580.79% |
| Mar 31, 2025 | -428.18% |
| Dec 31, 2024 | -730.74% |
| Sep 30, 2024 | -427.18% |
| Jun 30, 2024 | -880.88% |
| Mar 31, 2024 | -735.59% |
| Dec 31, 2023 | -1,469.61% |
| Sep 30, 2023 | -856.01% |
| Jun 30, 2023 | -385.41% |
| Mar 31, 2023 | -2,433.13% |
| Dec 31, 2022 | -686.14% |
| Sep 30, 2022 | -1,231.68% |
| Jun 30, 2022 | -1,321.70% |
| Mar 31, 2022 | -5,328.69% |
| Dec 31, 2021 | -1,679.58% |
| Sep 30, 2021 | -7,764.29% |
| Jun 30, 2021 | -2,849.35% |
| Mar 31, 2021 | -3,445.68% |
| Dec 31, 2020 | -2,153.70% |